Aim: The risk of developing a malignant tumor is increased for children infected with HIV. Many malignancies are linked with immunosuppression and oncogenic coinfection in children who are infected with HIV. In general, the majority of children living with HIV live in Sub-Saharan Africa, but the population is little aware of the malignancy of development. The present literature on the study of the spread of diseases and regulation of malignant development in HIV infected children is discussed in this paper. Methods and Results: Combination antiretroviral therapy (CART) decreases the risk of HIV-infected young people being malignant. In young people with earlier ARTs or more emergence of immunosuppression, the risk of disease is high compared with the younger ones who start ART and have milder immunosuppression. Our current research was conducted at Sir Ganga Ram Hospital, Lahore from May 2019 to April 2020. The risk of disease is greater. Therapy is important to avoid disease in children infected by HIV until serious Immunosuppression begins, but most young people in low-income countries initiate therapy to intense immunosuppressive stages. Immunization against high-risk variations of the human papillomavirus could lead to the recurrence of human papillomavirus-related malignant growth at some point in time. Nevertheless, the adaptation of HPV immunization rules to young men and women infected with HIV remains a question to be answered when deciding on the best immunization systems. Discussion: Better awareness is needed about the current and continuing hazards of disease development and the effects of HIV/AIDS preventive action on HIV infected youth locally. Keywords: HIV-infected children's pharmacology, cancer prevention.